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ABSTRACT
Hepatocellular carcinoma (HCC) has one of the worst prognoses amongst all 
malignancies. It commonly arises in patients with established liver disease and 
the diagnosis often occurs at an advanced stage. Genetic variations, such as single 
nucleotide polymorphisms (SNPs), may alter disease risk and thus may have use 
as predictive markers of disease outcome. The aims of this study were (i) to assess 
the association of two SNPs, rs430397 in GRP78 and rs738409 in PNPLA3 with the 
risk of developing HCC in a Sicilian association cohort and, (ii) to use a machine 
learning technique to establish a predictive combinatorial phenotypic model for HCC 
including rs430397 and rs738409 genotypes and clinical and laboratory attributes. 
The controls comprised of 304 healthy subjects while the cases comprised of 170 HCC 
patients the majority of whom had hepatitis C (HCV)–related cirrhosis. Significant 
associations were identified between the risk of developing HCC and both rs430397 
(p=0.0095) and rs738409 (p=0.0063). The association between rs738409 and HCC 
was significantly stronger in the HCV positive cases. In the best prediction model, 
represented graphically by a decision tree with an acceptable misclassification rate of 
17.0%, the A/A and G/A genotypes of the rs430397 variant were fixed and combined 
with the three rs738409 genotypes; the attributes were age, sex and alcohol. These 
results demonstrate significant associations between both rs430397 and rs738409 and 
HCC development in a Sicilian cohort. The combinatorial predictive model developed 
to include these genetic variants may, if validated in independent cohorts, allow for 
earlier diagnosis of HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common of the primary liver cancers. It is the fifth most 
common malignancy worldwide and the third most frequent 
cause of cancer-related deaths [1–3]. The epidemiology of 
HCC is complex reflecting, to a large extent, differences 
in levels of exposure to known predisposing factors 
such as the presence of cirrhosis, chronic infection 
with hepatitis B virus (HBV) and hepatitis C virus 
(HCV) and environmental toxin exposure. Prevalence 
rates are 16 to 32 times higher in economically less- 
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developed countries such as sub-Saharan Africa South-east 
Asia and China [4]. In Eastern Asia the major risk factor 
for HCC is infection with hepatitis B [5, 6], whereas in 
Northern and Western Europe excess alcohol consumption 
and infection with HCV are the main antecedents [3]. In 
developed countries HCC develops most frequently in 
patients with established cirrhosis whereas elsewhere HCC 
may arise in patients with chronic HBV and HCV infection 
at a pre-cirrhotic stage [7, 8]. There are also data to support 
a role for tobacco smoking, diabetes and obesity as risk 
factors or risk co-factors for the development of HCC [9]. 
Finally there are important gender differences in HCC 
prevalence; men are at two- to five-fold increased risk of 
developing this malignancy than women, depending on 
geographic area, which most likely reflect their increased 
exposures to known risk factors [1].
As the epidemiology of HCC has become better 
understood, so has the fact that only 5 to 20% of the 
populations potentially at risk actually develop HCC. 
Interest has, therefore, turned to the identification of 
the factors responsible for the differences in individual 
susceptibility; in particular the role of genetic variation. 
Two of the most notable genetic findings to date have 
been the association between the Single Nucleotide 
Polymorphisms (SNP), rs430397 and rs738409, with HCC 
risk. The rs430397 variant in glucose regulated protein 
78 (GRP78 also known as HSPA5) has been associated 
with HCC and cirrhosis risk in Chinese populations with 
HBV infection [10, 11]. There is considerable functional 
and genetic evidence implicating the GRP78 protein in 
mechanisms of HCC carcinogenesis [12, 13] and indeed in 
malignancies at other sites [14, 15]. The rs738409 variant in 
patatin-like phospholipase domain-containing 3 (PNPLA3) 
has been identified as conferring a significant risk for 
developing cirrhosis in relation to non-alcohol-related fatty 
liver disease [16] and alcohol-related liver disease [17]. 
The rs738409 variant not only contributes to liver injury, 
but also to the risk of development of subsequent HCC [18, 
19]. The nature of the association between the rs738409 
variant in HCV-related HCC is less well characterized 
than in HCC of other aetiologies possibly because there is 
significant heterogeneity in the study populations in which 
this variant has been studied [20].
Variants in GRP78 and PNPLA3 have been 
associated with HCC risk in populations of diverse 
ancestry and with HCC of diverse aetiology. It is not 
known, however what proportion of the variance in 
HCC risk can be attributed to genetic factors in Southern 
European populations in whom the main risk factor for 
the development of HCC is chronic HCV infection and 
the incidence is rising [9]. Further, it is widely recognized 
that HCC risk prediction in chronic liver disease will have 
clinical utility in guiding evidence-based decisions about 
patient management [21] but it is unclear as to whether 
genetic information could improve the predictive models. 
Machine learning techniques have the potential to improve 
the accuracy of predictive models using genetic data [22]. 
A number of machine learning techniques have been 
developed, but all make use of computer algorithms that 
improve predictive accuracy with experience. Decision 
tree algorithms in particular are a well-established 
technique, which are useful for exploratory analysis and 
model visualisation.
The aims of the present study were therefore to 
assess, whether (i) two genetic variants in PNPLA3 and 
GRP78 are associated with the risk of developing HCC 
in a Sicilian population, and (ii) whether inclusion of 
genotypic information would contribute to a predictive 
model designed to stratify patients by HCC risk.
RESULTS
Cohort characteristics
The cases were significantly older than the healthy 
controls (mean ± 1SD age 70.2± 8.0 vs. 56.6 ± 8.1 years; 
p = 2.2 x 10-16) and comprised of proportionately fewer 
men (70.4% vs. 58.2%, p = 0.007) (Table 1). All but one 
of the cases had established cirrhosis; in the majority 
chronic HCV infection was the aetiological agent (Table 
1). A small proportion of patients (n=12; 7%), had marked 
steatosis in addition to cirrhosis. Up to 40% of the cases 
had experienced a major complication of chronic liver 
disease; and the majority had features of hepatocellular 
dysfunction with poor synthetic and excretory function 
(Table 2). Features of cirrhosis were evident on imaging in 
all included cases; ultrasonography was the modality most 
frequently employed (Table 2). The diagnosis of HCC was 
made in the majority on the basis of multimodal imaging; 
less than a quarter of patients had an elevated serum alpha-
fetoprotein level (Table 3).
Genotyping quality
The genotyping success rate was greater than 95% 
for both variants, with genotype distributions showing no 
evidence for deviation from Hardy-Weinberg equilibrium in 
controls (p >0.05). The minor and major allele designations 
of both rs430397 and rs738409 were generally similar in 
this Sicilian ancestry cohort to those in reference Europeans 
ancestry groups [23]; however, the minor allele (G) of 
rs738409 was noticeably more frequent in Sicilian controls 
than in European reference populations.
GRP78 and PNPLA3 polymorphisms and HCC
Both rs430397 in GRP78 and rs738409 in PNPLA3 
were significantly associated with HCC risk in this Sicilian 
ancestry cohort (Table 4). The association between 
rs430397 in GRP78 and HCC risk is best described by a 
dominant model (AA+AG vs. GG), (p= 0.0095, OR= 1.81) 
whereas the association between rs738409 in PNPLA3 is 
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best described by a recessive model (GG vs. CG +CC), 
(p= 6.28x10-3, OR= 2.56) (Table 5).
When the analyses were confined to cases with 
HCC related to chronic HCV infection there was no 
evidence of association between rs430397 in GRP78 
and HCC risk (Table 5). Because the frequency of the 
rs430397: AA genotype in this stratified cohort was 
very low, an association test under a recessive model of 
inheritance (AA vs. AG+GG) could not be performed 
using logistic regression. In contrast, the magnitude of the 
association between rs738409 in PNPLA3 and HCC risk 
increased when confined to the HCV positive HCC cases 
(p=2.41x10-3, OR=2.82) (Table 5). There was no evidence 
for an epistatic interaction between the two variants and 
HCC risk (Pasymptotic = 0.8, ORinteraction = 1.08). None of the 
demographic, clinical, laboratory or diagnostic variables 
was associated with either the GRP78 or PNPLA3 
genotypes (Table 6).
Table 1: Characteristics of the healthy controls and HCC cases included in the genetic association study
Variable Controls (n=304) HCC cases (n=170)
Age at diagnosis (yr) 56.6 ± 8.1 70.2 ± 8.0
Gender
 Men 214 (70.4) 99 (58.2)
 Women 90 (29.6) 71 (41.8)
Aetiology of Liver Disease
 HCV 144 (84.7)
 Alcohol 10 (5.9)
 Cryptogenic 10 (5.9)
 HBV 9 (5.3)
 Dysmetabolic syndrome 1 (0.6)
Data are mean ± 1SD or number (%)
Abbreviations: HCV- hepatitis C virus; HBV- hepatitis B virus.
Table 2: Historical, clinical, laboratory, imaging and histological information used to diagnosis cirrhosis in the HCC 
cases
Variables used to diagnose cirrhosis Cases (n=170)
History and clinical findings Affected/abnormal n (%)
Variceal hemorrhage 66 (38.8)
Ascites 44 (25.9)
Hepatic encephalopathy 10 (5.9)
Laboratory investigations
Thrombocytopaenia* 137 (80.6)
Prolonged prothrombin time* 53 (31.2)
Hypoalbuminaemia* 13 (7.6)
Hyperbilirubinaemia* 11 (6.5)
Investigations including imaging
Ultrasound 163 (95.9)
CT-Scan 8 (4.7)
Endoscopy 5 (2.9)
Histology 20 (11.8)
* Laboratory cut-off values: platelet count: < 150 x 109/L, Prothrombin time > 40 sec,
plasma albumin < 35 g/L, serum bilirubin > 1.2 mg/dl.
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Table 3: Laboratory, imaging and histological information used to diagnose HCC
Variables used to diagnose cirrhosis Cases (n=170)
Laboratory Investigations Affected/abnormal n (%)
Elevated serum alpha-fetoprotein* 37 (21.8)
Imaging
CT-Scan 146 (85.9)
Ultrasound 27 (15.9)
MRI-Scan 27 (15.9)
Histology 20 (11.8)
* Laboratory cut-off values: serum alpha-fetoprotein > 400 ng/ml.
Table 4: Allelic associations between the SNPs rs430397 and rs738409 in sicilian cases with HCC and healthy 
controls
Gene (SNP) Group n Minor Allele
Genotype Counts
MAF
Cases vs Controls
Significance p OR (95% CI)
AA AG GG
GRP78 
(rs430397)
Cases 170
A
1 46 123 0.141
0.016
1.65  
(1.09-2.50)Controls 304 2 51 251 0.090
GG CG CC
PNPLA3 
(rs738409)
Cases 170
G
35 64 71 0.39
4.22x10-3
1.50  
(1.14-1.98)Controls 304 28 128 148 0.30
Abbreviations: SNP – Single nucleotide polymorphism; n – number; MAF – Minor allele frequency; OR: Odds ratio; CI: 
Confidence Interval.
Table 5: Associations between rs430397 and rs738409 genotypes in sicilian cases with HCC and healthy controls 
using different genetic models
Gene (SNP) Model
Entire cohort (n=474) Entire cohort excluding non HCV-related cases (n=448)
P OR 95% CI P OR 95% CI
GRP78  
(rs430397)
Allelic 0.014 1.71 1.11-2.63 0.0348 1.64 1.04-2.58
Dominant 0.0095 1.81 1.16-2.83 0.0190 1.76 1.10-2.82
Recessive 0.93 0.89 0.08-9.93 - - -
PNPLA3  
(rs738409)
Allelic 0.0065 1.45 1.11-1.90 0.00363 1.52 1.15-2.02
Dominant 0.15 1.32 0.91-1.93 0.127 1.37 0.92-2.04
Recessive 0.0063 2.56 1.49-4.38 2.41x10-3 2.82 1.62-4.90
Abbreviations: SNP – Single nucleotide polymorphism; OR: Odds ratio; CI: Confidence Interval.
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Table 6: Association between rs430397 and rs738409 and demographic, clinical and laboratory variables in the HCC 
cases
Characteristics
rs430397 rs738409
A/A + G/A 
(n=47)
G/G 
(n=123) p C/C (n=71) C/G (n=64)
G/G 
(n=35)
p  
(C/C vs 
C/G)
p  
(C/C vs 
G/G)
Age (years):
<71 21 (44.7%) 59 (48%) 35 (49.3%) 31 (48.4%) 14 (40%) 0.942 0.4867
>=71 26 (55.3%) 64 (52%) 0.832 36 (50.7%) 33 (51.6%) 21 (60%)
Gender:
M 23 (48.9%) 76 (61.8%) 44 (62%) 38 (59.4%) 17 (48.6%) 0.895 0.270
F 24 (51.1%) 47 (38.2%) 0.178 27 (38%) 26 (40.6%) 18 (51.4%)
HCV:
Yes 39 (83%) 105 (85.4%) 59 (83.1%) 53 (82.8%) 32 (91.4%) 0.853 0.389
No 8 (17%) 18 (14.6%) 0.882 12 (16.9%) 11 (17.2%) 3 (8.6%)
HBV:
Yes 3 (6.4%) 6 (4.9%) 5 (7%) 3 (4.7%) 1 (2.9%) 0.831 0.667
No 44 (93.6%) 117 (95.1%) 0.993 66 (93%) 61 (95.3%) 34 (97.1%)
Alcohol:
Yes 3 (6.4%) 7 (5.7%) 4 (5.6%) 6 (9.4%) 0 (0%) 0.617 0.374
No 44 (27.5%) 116 (94.3%) 0.847 67 (94.4%) 58 (90.6%) 35 (100%)
Cirrhosis:
Yes 47 (100%) 122 (99.2%) 71 (100%) 64 (100%) 34 (97.1%) 0.606 0.717
No 0 (0%) 1 (0.8%) 0.616 0 (0%) 0 (0%) 1 (2.9%)
Cryptogenic:
Yes 4 (8.5%) 6 (4.9%) 4 (5.6%) 4 (6.2%) 2 (5.7%) 0.831 0.667
No 43 (91.5%) 117 (95.1%) 0.592 67 (94.4%) 60 (93.7%) 33 (94.3%)
Dysmetabolic:
Yes 0 (0%) 1 (0.8%) 0 (0%) 1 (1.6%) 0 (0%) 0.958 7.00x10-3
No 47 (100%) 122 (99.2%) 0.616 71 (100%) 63 (98.4%) 35(100%)
Ascites:
Yes 11 (23.4%) 33 (26.8%) 22 (31%) 12 (18.8%) 10 (28.6%) 0.958 0.976
No 36 (76.6%) 90 (73.2%) 0.795 49 (69%) 52 (81.2%) 25 (71.4%)
Variceal hemorrhage:
Yes 16 (34%) 50 (40.7%) 28 (39.4%) 19 (29.7%) 19 (54.3%) 0.314 0.215
No 31 (66%) 73 (59.3%) 0.539 43 (60.6%) 45 (70.3%) 16 (45.7%)
Hepatic encephalopathy:
Yes 1 (2.1%) 9 (7.3%) 6 (8.5%) 2 (3.1%) 2 (5.7%) 0.345 0.912
No 46 (97.9%) 114 (92.7%) 0.357 65 (91.5%) 62 (96.9%) 33 (94.3%)
(Continued)
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Modelling of phenotypes and PNPLA3/GRP78 
polymorphisms in the HCC cases
The first decision tree included different 
combinations of rs430397 and rs738409 genotypes, and 
the attributes of: age, sex, HCV status, ascites, variceal 
haemorrhage, prolonged prothrombin time and elevated 
serum alpha-fetoprotein (Figure 1). This decision tree had 
a misclassification rate (MCR) of 40%.
The second decision tree included only three 
possible genotypic combinations: the rs430397 G/G was 
fixed and combined with the three rs738409 genotypes; 
the discriminating attributes were age, sex, HBV status, 
steatosis, ascites, variceal haemorrhage, thrombocytopenia, 
prolonged prothrombin time, elevated serum alpha-
fetoprotein (Figure 2). The predictive power of this decision 
tree substantially improved resulting in a MCR of 24.4%.
The third decision tree, which was complimentary 
to the second, kept only A/A and G/A genotypes of the 
rs430397 variant and the discriminating attributes: age, 
sex and alcohol. This was the most discriminating of the 
decision trees with a MCR of 17.0% (Figure 3).
DISCUSSION
The high variability of HCC incidence worldwide 
undoubtedly relates to differences in the distribution of 
environmental risk factors and most likely to variations 
in genetic susceptibilities between ethnic groups [24]. 
Outcomes in patients with HCC are critically dependent 
on early detection and diagnosis and hence the efficacy 
of public health strategies and screening programs [5]. 
The success of these programs, in turn, depends on the 
availability of validated, predictive markers with high 
sensitivity and specificity.
In the present study, two SNPs, rs430397 in GRP78 
and rs738409 in PNPLA3, were shown to be significantly 
associated with the risk of developing HCC in a Sicilian 
population. Further the possibility that these risk-associated 
genetic variants could be used to prediction the development 
of HCC on an individual patient basis was explored, using a 
machine learning technique, with promising results.
Rs430397 lies in the fifth intron of GRP78. It has 
been associated with HCC risk in Chinese with HBV 
infection [10, 11] but does not appear to have been studied 
in European populations previously. As a non-protein-
coding SNP, it could influence gene/protein function by 
altering gene expression but there is no direct evidence, to 
date, that this variant has functional effects. However, it 
does not lie in a GRP78 gene region associated with high 
transcriptional activity [25] nor in a CpG island associated 
with epigenetic mechanisms of gene silencing (T. Mazza: 
personal communication October 2016).
Physiologically the GRP78 protein acts as a 
molecular chaperone, which is activated by endoplasmic 
reticulum stress [26] and is involved in intracellular 
Characteristics
rs430397 rs738409
A/A + G/A 
(n=47)
G/G 
(n=123) p C/C (n=71) C/G (n=64)
G/G 
(n=35)
p  
(C/C vs 
C/G)
p  
(C/C vs 
G/G)
Thrombocytopaenia:
Yes 42 (89.4%) 95 (77.2%) 55 (77.5%) 52 (81.5%) 30 (85.7%) 0.742 0.458
No 5 (10.6%) 28 (22.8%) 0.116 16 (22.5%) 12 (18.8%) 5 (14.3%)
Prolonged prothrombin 
time
Yes 16 (34%) 37 (30.1%) 23 (32.4%) 20 (31.2%) 10 (28.6%) 0.966 0.860
No 31 (66%) 86 (69.9%) 0.754 48 (67.6%) 44 (68.7%) 25 (71.4%)
Hyperbilirubinaemia
Yes 5 (10.6%) 6 (4.9%) 3 (4.2%) 5 (7.8%) 3 (8.6%) 0.606 0.643
No 42 (89.4%) 117 (95.1%) 0.309 68 (95.8%) 59 (92.2%) 32 (91.4%)
Hypoalbuminaemia
Yes 4 (8.4%) 9 (7.3%) 4 (5.6%) 7 (10.9%) 2 (5.7%) 0.418 0.667
No 43 (91.5%) 114 (92.7%) 0.952 67 (94.4%) 57 (89.1%) 33 (94.3%)
Raised serum 
alphafetoprotein
Yes 8 (17%) 29 (23.6%) 0.472 16 (22.5%) 16 (25%) 5 (14.3%) 0.894 0.458
No 39 (83%) 94 (76.4%) 55 (77.5%) 48 (75%) 30 (85.7%)
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Figure 1: Decision tree based on the genotypes of both PNPLA3 and GRP78 SNPs. In this analysis the included discriminating 
attributes were: age, sex, HCV status, ascites, variceal haemorrhage, prolonged prothrombin time (PTT), elevated serum alpha-fetoprotein 
(AFP). The first genotype refers to the rs430397 variant and the second, separated by “-”, refers to the rs738409 variant. The ratio of the 
genotypes accurately classified over those wrongly classified is provided for each genotype in brackets.
Figure 2: Decision tree developed fixing the rs430397 G/G genotype. In this analysis, the most discriminating attributes were: 
age, sex, HBV, steatosis, ascites, variceal haemorrhage, thrombocytopenia, prolonged prothrombin time (PTT), elevated serum alpha-
fetoprotein (AFP). The genotype in the box refers to rs738409. The ratio of the genotypes accurately classified over those wrongly classified 
is provided for each genotype in brackets.
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calcium ion homeostasis [27]. It has also been reported to 
sustain cell survival, to inhibit apoptosis and to promote 
the invasion and metastasis of HCC cells in vitro [28–31]. 
However, the precise role of GRP78 in the development of 
cancer is still not clear [32, 33].
Rs738409 lies in the third exon of PNPLA3 and 
encodes a nonsynonymous alteration in the protein 
sequence (Ile148Met). This SNP came to prominence 
when identified as a risk factor for the progression of non-
alcohol related fatty liver disease [16] and the development 
of alcohol-related cirrhosis [17]. Subsequently, the risk 
allele of rs738409 was shown to be associated with the 
development of HCC in patients of European descent 
with established cirrhosis [20]. Rs738409 has also been 
associated with the development of HCC in East Asian 
populations [34, 35]. The risk allele of rs738409 has 
also been studied in relation to HCV-related liver injury, 
although associations are less consistent [36, 37]. The 
results of the present study show that the rs738409:G allele 
is a significant risk for HCC in the Sicilian population. 
The fact that the strength of the association was increased 
in the subgroup with HCV-related cirrhosis with an 
effect size that exceeds that in many other studies is of 
interest but has to be weighed against the fact that these 
individuals comprised almost 85% of the study population.
Despite the substantial genetic evidence implicating 
rs738409 and PNPLA3 with cirrhosis and HCC of different 
aetiologies, the function of the PNPLA3 protein remains 
uncertain as does the effect of the Ile148Met substitution. 
The 148Met risk allele appears to promote intracellular 
triglyceride retention [38] but the functional changes that 
lead to the development of significant liver damage and 
HCC remain to be established. Of interest the association 
between rs738409 and liver disease progression appears 
to be independent of the severity of liver fat accumulation 
[20, 39]. Further, the functional effects of this variant may 
directly or indirectly regulate the release of molecules 
Figure 3: Decision tree developed fixing the rs430397 A/A and G/A genotypes. This analysis selected the age, sex and alcohol 
variables. The genotype in the box refers to the rs738409 SNP. The ratio of the genotypes accurately classified over those wrongly classified 
is provided for each genotype in brackets.
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involved in inflammation and fibrogenesis as intercellular 
adhesion molecule 1 and adiponectin [40–43].
The MAF of the rs738409 variant in the Sicilian 
control population utilized in the present study was 
higher than expected when compared with an ancestrally 
appropriate European reference population, e.g. the Toscani 
from Italy [23] (30% cf. 23%). This difference in allele 
frequency could reflect genetic isolation of the population 
of Sicily. However, a recent study has shown that Sicilians 
are genetically similar to mainland Italians from the 
adjacent regions [44]. Another potential explanation for 
this observation could be cryptic underlying population 
stratification, which may have arisen due to the use of blood-
donor controls. Despite this, similar blood-donor controls are 
used in the Wellcome Trust Case-Control consortium cohort 
[45] with little evidence to suggest significant population 
stratification in their analyses.
There was no evidence, in the present study, of an 
epistatic interaction between the GRP78 and PNPLA3 
variants in relation to HCC risk. In addition there were 
no significant associations between either variant and any 
clinical features or the results of any of the laboratory 
investigation. However, combinations of these various 
attributes together with the rs430397 and rs738409 
genotypes were used to produce a model, graphically 
displayed as a decision tree, which could be useful for 
predicting subjects at risk for developing HCC, at least 
within this study population. The best prediction model 
used only age, sex and alcohol as the additional required 
variables and was represented by a decision tree with a 
MCR of 17.0%.
In conclusion: rs430397 in GRP78 and rs738409 in 
PNPLA3 are risk factors for the development of HCC in 
a Southern Italian population of cases with predominantly 
HCV-related cirrhosis. Use of a machine-learning 
approach allowed development of a prediction model 
incorporating phenotypic, clinical and genotypic variables. 
This computational approach needs to be further explored 
and the predictions independently validated. If confirmed, 
this approach could be used to identify individuals at risk 
at an early stage thereby facilitating monitoring and, when 
required, early intervention.
PATIENTS AND METHODS
Study populations
The 170 HCC cases were enrolled at the Department 
of Internal Medicine and Medical Specialties of the 
Policlinico Hospital, Palermo, Italy. All had been born 
in Sicily and continued to reside there. The aetiology 
of the liver disease was determined using historical, 
clinical, laboratory, imaging and histological information. 
The diagnosis of cirrhosis and HCC were made based 
on previously reported criteria [46], and international 
guidelines [47]. In the majority of instances the diagnosis 
of cirrhosis was based on historical, clinical, laboratory 
and radiological variables; histological confirmation was 
available in a minority from liver biopsy material obtained 
via the percutaneous route (Table 2). The diagnosis of 
HCC was based on historical, clinical, and laboratory 
variables together with, as recommended, multimodal 
imaging (Table 3). The 304 healthy blood donors, who 
acted as controls, were recruited at the Azienda di Rilievo 
Nazionale ad Alta Specialiazzione (A.R.N.A.S.) Civico 
Hospital of Palermo, Italy. Controls were only included if 
they were born in and continued to reside in Sicily; were 
aged > 30 years and in line with International guidelines 
[48, 49] were negative for HBsAg, anti-HCV and anti HIV 
antibodies and had normal routine blood test results.
All included cases and controls provided written 
informed consent. This research was approved by the 
Ethics committee of the Policlinico Hospital (Palermo, 
Italy).
DNA extraction and genotyping
Genomic DNA was extracted from whole 
blood using the WizardGenomic DNA Purification 
Kit (Promega). DNA quality was assessed using gel 
electrophoresis (0.8% agarose gel; 5 volts/cm for 1 hour; 
1× Tris-borate-EDTA (TBE) buffer; 100 bp and 1kb DNA 
Ladder (Promega, UK). Genotyping for rs430397 in 
GRP78 and rs738409 in PNPLA3 was performed using 
the K-Biosciences Competitive Allele Specific PCR (LGC 
Genomics, Hoddesdon, UK) platform with amplification 
and detection undertaken using a LightCycler® 480 real-
time PCR system (Roche Molecular Diagnostics, Burgess 
Hill, UK). Genotype calling was performed automatically 
using proprietary software with minor manual editing of 
genotype calls. Approximately 12% of samples, randomly 
selected a priori, were genotyped in duplicate to ensure 
consistent genotype calling. The primers used for KASPar 
genotyping are detailed in Supplementary Table 1.
Statistical analysis
Genetic analysis
Tests for genetic association, missingness, deviation 
from Hardy-Weinberg equilibrium and epistasis were 
performed using PLINK (version 1.9) [50]. Genetic 
association analyses were performed using logistic 
regression utilizing additive, dominant and recessive 
models when comparing HCC cases and controls. Tests 
for association between demographic covariates were 
performed under an additive model using the Fisher’s 
exact test to assess significance. Statistical analyses were 
performed in R [51].
Prediction modelling
A two-step analysis comprising of variable 
selection and decision tree construction was performed 
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using a machine learning technique to establish a rule 
for predicting phenotypes starting from the genotypes of 
both the rs430397 and rs738409 variants. In the first step 
the variables to be used in the second step were selected 
utilizing a stepwise search, which performs a greedy 
forward or backward search through the space of HCC 
case characteristics or attributes. The selection is based on 
a decision tree classifier for estimating the accuracy of the 
chosen variable subset and is stopped when the addition/
deletion of any remaining attribute resulted in a decrease 
in evaluation. The second step involved the construction 
of a tree-like graph or model of decisions based on the 
previously selected variables. This model exhibits a 
flowchart-like structure in which each internal node 
represents a ‘test’ on an attribute, each branch represents 
the outcome of the test and each leaf node represents a 
class label. The paths from root to leaves represent the 
classification rules. The evaluation of the classifier is 
based on the overall misclassification rate (MCR); the 
lower the MCR the better the prediction modelling. Both 
steps were performed using the RWeka package (R-3.2.3 
software).
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